Meet AZN management: ASCO 2020
Virtual breakout 1: Tagrisso and immuno-oncology

Dave Fredrickson, Cristian Massacesi
IR moderator: Craig Marks

1 June 2020
Webinar is being recorded
Forward-looking statements disclaimer

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.
Delivering further improvements in patient outcomes

Tagrisso: standard of care in EGFRm

20 countries
1L reimbursed (approved in 81)

• Standard of care, Stage IV NSCLC
  - EGFRm (1L)
  - T790M (2L)
• Exclusivity into the 2030s

46 countries
2L reimbursed (approved in 88)

• Reimbursement expanding in 1L, including potential for NRDL\textsuperscript{1} inclusion in H2 2020; growth in the metastatic setting weighted outside the US
• Lifecycle management in early disease, treating resistant/emerging populations with combinations

1. National reimbursement drug list (reimbursement guidelines in China).
**Tagrisso**

The first TKI\(^1\) in early disease; opportunities across mono and combo

---

**ADAURA at ASCO 2020**

Unprecedented disease-free survival

---

**Lifecycle management in EGFR disease**

- **Early**
  - Move Tagrisso to curative setting
  - Lung cancer stages:
    - Active disease, Stage IB-IIIA, resectable
    - Active disease, Stage III, locally advanced, unresectable

- **Metastatic**
  - Extend survival with use of 'best EGFR-TKI first'
  - T790M-
  - T790M+
  - Non-T790M-driven resistance
  - CTx, IO
  - Post-1L Tagrisso combinations
  - ORCHARD 2021+
  - SAVANNAH 2021+

---

**Covering a high number of lung cancers**

NSCLC patient numbers per year (thousands, all-comers)

---

\(^1\) Tyrosine kinase inhibitor.

Source: ASCO 2020, abstract LBA5. Stage IB to IIIA; disease-free survival (DFS) by investigator assessment.

---

2. Chemotherapy.

Source: AstraZeneca data on file.
**IO: Imfinzi**
Unique position in lung cancer

### Stage III, unresectable NSCLC
- **27 countries** reimbursed (approved in 62)

### Extensive-stage SCLC
**Final OS¹ analysis**
- Differentiated clinical profile
- Physicians’ choice of CTx
- Long-term survival (22% of patients alive at two years) with durable responses (>10% still on treatment)

### Major lung cancer news flow

**Early**
- PACIFIC
- PACIFIC-4 2021+
- PACIFIC-5 2021+
- AEGEAN 2021+
- BR.31 2021
- MERMAID-1 New 2021+
- ADRIATIC 2021+

**Metastatic**
- CASPIAN
- PEARL 2021+
- POSEIDON

---

1. **Overall survival.**
   D = durvalumab (Imfinzi), EP = etoposide 80-100mg/m² with either carboplatin AUC 5-6 or cisplatin 75-80mg/m². Source: ASCO 2020, abstract 9068.

---

**Product sales at actual exchange rates.**

**Scope to extend reimbursement**

**Further potential within lung cancer**

---

**Source:** AstraZeneca data on file.
**IO: strategic optionality**

Unique position in early and metastatic disease

---

**First**

Potential to cure patients in early disease

**First**

Potential to disrupt in metastatic disease

---

**PACIFIC: PFS**¹ (primary endpoint; intent to treat)

**Novel modes of action/combos**

- Combinations
  - Adenosine pathway inhibition
  - PD-1/CTLA-4 bispecific
  - Oncolytic viruses

**Biomarker strategies**

- TMB
- PD-L1
- ctDNA
- HER2

---

1. Progression-free survival.

Source: ESMO 2017, abstract LBA1_PR.
**IO: refreshed focus**

**Advancement in liver cancer**

### Study 22 Phase Ib/II

Single priming dose with tremelimumab in advanced hepatocellular carcinoma after sorafenib (four treatment arms; no comparator)

<table>
<thead>
<tr>
<th>T300+I</th>
<th>I</th>
<th>T</th>
<th>T75+I</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>75</td>
<td>104</td>
<td>69</td>
</tr>
</tbody>
</table>

Median OS, months (95% CI)

- T300+I: 18.73 (10.78-27.27)
- I: 13.57 (8.74-17.64)
- T: 15.11 (11.33-20.50)
- T75+I: 11.3 (8.38-14.95)

**Best median OS with treme300 + Imfinzi**

1. T300 = tremelimumab 300mg
2. T75 = tremelimumab 75mg
3. One event observed at 27 months in the T300+I arm. Source: ASCO 2020, abstract 4508.

### Major Phase III liver cancer news flow, starting in H2 2020

**Emerald-1**

2021

**Emerald-2**

2021+

**Himalaya**

H2 2020

**Topaz-1**

2021+

**Multiple potential catalysts**

**Hepatocellular carcinoma**

Biliary-tract cancer

Source: AstraZeneca data on file.

### Hepatocellular carcinoma epidemiology comparisons

- Locoregional hepatocellular carcinoma (HCC): 163,000
- Resectable HCC, at high risk of recurrence after surgery or radiofrequency ablation: 146,000
- Stage IV HCC, 1L, unresectable: 73,000

*Top 8 countries, estimated number of treated patients. For full details, please see the epidemiology fact sheet on astrazeneca.com/investors.*
To ask a question

Webinar
Click ’Raise Hand’ (preferred):

or type your question into the Q&A box (alternative)

Phone
*6 - Toggle mute/unmute
*9 - Raise hand
Use of AstraZeneca conference call, webcast and presentation slides

The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca Materials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any other material. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com